ArticleJournal of materials science. Materials in medicine2025
Preparation of human serum albumin-doxorubicin modified carbon nanotubes mediated combined photothermal and chemotherapeutic strategies in melanoma application.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Melanoma is an aggressive malignancy that requires novel treatment strategies. Herein, we developed a multi-walled carbon nanotube-based nanoplatform (MWCNTs/HSA-DOX) co-loaded with human serum albumin and doxorubicin for combinatorial therapy. The nanocomplexes served as highly effective photothermal agents, elevating the temperature to 52.8 °C upon NIR irradiation, and also displayed pH-sensitive drug release. In vitro studies against B16F10 melanoma cells demonstrated potent synergistic effects: the system achieved significant cell killing (viability <50% at 50 μg/mL) and promoted marked apoptosis, as evidenced by the profound upregulation of key pro-apoptotic proteins (caspase-3: 1.85-fold; Bax: 2.26-fold) and downregulation of Bcl-2 (0.44-fold). Our work highlights MWCNTs/HSA-DOX as a promising nanomedicine that successfully integrates photothermal ablation with controlled chemotherapy to trigger enhanced apoptotic death in melanoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.